Want to see IN:SPARC full AI Analyst Report?
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹108.20 - ₹289.00
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹73.86B
Enterprise Value₹42.77K
Total Cash (Recent Filing)₹26.20M
Total Debt (Recent Filing)₹5.59B
Price to Earnings (P/E)4.8
Beta1.76
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)47.85
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.78
Price to Sales (P/S)1.98
P/FCF Ratio-12.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing ModelSPARC's business model emphasizes out-licensing, milestone and royalty income plus R&D services. This asset-light model lets the company transfer late-stage commercialization costs to partners, generate recurring milestone/royalty streams, and scale returns without proportional capital expenditure.
Improved FY2026 LeverageFY2026's lower debt-to-equity and stated improved balance-sheet capacity enhance SPARC's ability to fund R&D or absorb setbacks without immediate distress. Better leverage gives flexibility to pursue partnerships, raise project financing, or support clinical programs over the medium term.
Step-change In FY2026 RevenueA large reported revenue and profit rebound in FY2026 demonstrates successful monetization or milestone realization. If underlying drivers reflect durable partnerships or product progress, this strengthens cash generation potential and credibility with collaborators and funders over the coming quarters.
Bears Say
Persistent Cash BurnDespite reported profitability in FY2026, SPARC has negative operating and free cash flow in every year shown. Ongoing cash burn weakens earnings quality, forces reliance on external financing, milestones or parent support, and constrains sustained funding of clinical pipelines without dilution or debt.
Volatile Balance-sheet HistoryHistorical episodes of negative equity and unstable leverage indicate financial volatility through cycles. Such swings increase refinancing and counterparty risk, complicate long-term planning, and may reduce bargaining power with partners or lenders during future funding rounds.
Prior Multi-year LossesThe company posted persistent losses and negative margins before FY2026, so the recent profit surge may reflect timing of milestones or one-offs. This track record raises doubt that margins and earnings are sustainably repeatable without consistent commercial successes or new durable revenue streams.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹108.20 and its highest was ₹289.00 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹73.86B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 9 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on May 18, 2026. The company reported ₹54.275 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of ₹54.275 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.886%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.
Technical Analysis
Jubilant Pharmova Limited
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Suven Life Sciences Limited
―
Suven Pharmaceuticals Ltd.
―